The facility in question is 500,000 square-feet and will provide UPM with more large-scare commercial capabilities to be utilized for manufacturing and packaging of solid oral dosage tablets and capsules in addition to semi-solid manufacturing of creams and ointments. As part of the purchase, UPM will continue to manufacture some of Pfizer's current products at the facility for the next two years. Read the full story.
